KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Total Non-Current Liabilities (2018 - 2025)

Vir Biotechnology's Total Non-Current Liabilities history spans 8 years, with the latest figure at $216.0 million for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 7.65% to $216.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $216.0 million, a 7.65% decrease, with the full-year FY2025 number at $216.0 million, down 7.65% from a year prior.
  • Total Non-Current Liabilities hit $216.0 million in Q4 2025 for Vir Biotechnology, up from $210.0 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for VIR hit a ceiling of $878.4 million in Q1 2022 and a floor of $205.3 million in Q2 2024.
  • Historically, Total Non-Current Liabilities has averaged $393.5 million across 5 years, with a median of $314.8 million in 2021.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 367.39% in 2021 and later tumbled 68.12% in 2024.
  • Tracing VIR's Total Non-Current Liabilities over 5 years: stood at $499.6 million in 2021, then skyrocketed by 42.72% to $713.0 million in 2022, then crashed by 56.1% to $313.0 million in 2023, then fell by 25.3% to $233.9 million in 2024, then dropped by 7.65% to $216.0 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for VIR at $216.0 million in Q4 2025, $210.0 million in Q3 2025, and $211.4 million in Q2 2025.